Asuragen and Wave partner to develop companion diagnostics for Huntington’s disease
The partnership will develop companion diagnostics for Wave’s investigational allele-selective therapeutic programmes targeting Huntington’s disease
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
The partnership will develop companion diagnostics for Wave’s investigational allele-selective therapeutic programmes targeting Huntington’s disease
Merit WRAPSODY endovascular stent graft system has almost completed its ‘First in Man’ studies, and is not currently…
The device is small in size, light in weight, round shaped, to fit into the back of a…
LivaNova’s Saluggia facility in Italy is dedicated for R&D and production of mechanical heart valves, rings, accessories, and…
The REGENETEN implant is delivered arthroscopically through a small incision over the location of the rotator cuff tendon…
The new tissue forms have been developed to advance the treatment of complex surgical wounds
The mobile, wearable device will enable to leave the hospital and be monitored from home
Axonics r-SNM System is said to be the first rechargeable SNM system approved for sale in the US,…
The new global innovation and development (GID) centre will help Phillips-Medisize to accelerate the creation of advanced drug…
The acquisition of Clear Genetics will help Invitae to enhance its ability to scale and deliver genetic information…